Table 4.
Adjusted hazard ratios (HRadj) and 95% confidence limits of the effect of pravastatin versus usual care on study outcomes, according to II, ID, and DD genotype strata. In addition, the adjusted interaction hazard ratios 1 (IHRadj) of the II versus the DD genotype and the ID versus DD genotype are given. The interaction hazard ratio estimates for a given outcome were obtained from respective Cox proportional hazards models incorporating treatment, genotype (II/DD and ID/DD), treatment by genotype interactions, and seven baseline covariates.
| HRadj (95% CI) | HRadj (95% CI) | HRadj(95% CI) | IHRadj (95% CI) | IHRadj (95% CI) | |
|---|---|---|---|---|---|
| Trial Outcome | II | ID | DD | II vs DD, p-value2 | ID vs DD, p-value2 |
| All-Cause Mortality | 0.90 (0.68, 1.18) | 0.99 (0.84, 1.16) | 1.09 (0.89, 1.35) | 0.81 (0.58, 1.14), 0.23 | 0.90 (0.69, 1.17), 0.42 |
| CVD Mortality | 0.79 (0.53, 1.18) | 0.98 (0.78, 1.24) | 1.10 (0.81, 1.50) | 0.70 (0.42, 1.15), 0.16 | 0.87 (0.59, 1.29), 0.49 |
| CHD | 0.84 (0.48, 1.46) | 1.00 (0.73, 1.37) | 1.01 (0.66, 1.53) | 0.82 (0.41, 1.64), 0.58 | 0.98 (0.58, 1.65), 0.94 |
| Fatal Stroke | 0.60 (0.26, 1.39) | 1.02 (0.53, 1.97) | 1.22 (0.64, 2.33) | 0.47 (0.16, 1.34), 0.16 | 0.83 (0.33, 2.10), 0.70 |
| Other CVD | 0.93 (0.42, 2.05) | 0.91 (0.60, 1.39) | 1.22 (0.63, 2.36) | 0.71 (0.26, 1.99), 0.52 | 0.71 (0.33, 1.55), 0.39 |
| Non-CVD Mortality | 1.04 (0.69, 1.55) | 1.00 (0.79, 1.27) | 1.09 (0.81, 1.48) | 0.95 (0.58, 1.57), 0.85 | 0.92 (0.63, 1.35), 0.67 |
| Fatal CHD and nonfatal MI | 0.84 (0.59, 1.18) | 0.84 (0.68, 1.03) | 0.99 (0.77, 1.27) | 0.84 (0.55, 1.29), 0.43 | 0.85 (0.61, 1.17), 0.31 |
| Stroke (fatal and nonfatal) | 0.73 (0.48, 1.11) | 0.88 (0.66, 1.19) | 1.03 (0.74, 1.43) | 0.69 (0.41, 1.19), 0.18 | 0.86 (0.55, 1.35), 0.52 |
| Heart Failure (hospitalized or fatal) | 0.75 (0.50, 1.14) | 1.15 (0.89, 1.48) | 0.85 (0.61, 1.20) | 0.87 (0.51, 1.49), 0.61 | 1.32 (0.86, 2.02), 0.20 |
Adjusted for differences in sex (male/female), race (black/white), and five baseline variables: current smoking status (yes/no), history of diabetes (yes/no), history of CHD (yes/no), systolic blood pressure level (mm Hg), age (years).
The interaction hazard ratio is a ratio of ratios: Prav/UC for II stratum over Prav/UC for DD stratum, and similarly for ID versus DD.
Test of null hypothesis: IHRadj = 1.0.